Fertility-preserving treatment in young women with endometrial cancer.
Nonsurgical fertility-preserving treatment of well-differentiated endometrial cancer with systemic progestins has been described for young women who desire to preserve their fertility. The overall response to progestin treatment in 9 retrospective studies is 79% with 79 subsequent live births. Recurrence can be expected in approximately 36-40% of conservatively treated patients who initially responded. Synchronous ovarian cancer has been reported in approximately 9%. However, amongst 162 receiving systemic, continuous treatment with progestins no death caused by cancer has been reported. We review guidelines for diagnosis, treatment and follow-up in young women undergoing conservative treatment for endometrial cancer.
Böing
Carsten
C
Department of Gynecology and Obstetrics, University of Essen, Essen, Germany. carsten.boeing@med.uni-essen.de
Kimmig
Rainer
R
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D007247:Infertility, Female / Q000517:prevention & control*; D009367:Neoplasm Staging; D011247:Pregnancy; D045167:Progesterone Congeners / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate
D018931:Antineoplastic Agents, Hormonal; D045167:Progesterone Congeners